Ascendis Pharma A/S

Ascendis Pharma A/S ROA

The Return on Assets (ROA) of Ascendis Pharma A/S (ASND) as of Nov 5, 2026 is -16.82 %. In the previous year, Return on Assets (ROA) was -32.05 % — a change of -47.52% (higher).

ROA

-16.82 %

YoY

-47.52%

Last updated:

In 2025, Ascendis Pharma A/S's return on assets (ROA) was -16.82 %, a -47.52% increase from the -32.05 % ROA in the previous year.

The Ascendis Pharma A/S ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-40.79 EUR
Jan 1, 2019
-32.22 EUR
Jan 1, 2020
-42.76 EUR
Jan 1, 2021
-35.36 EUR
Jan 1, 2022
-53.52 EUR
Jan 1, 2023
-58.32 EUR
Jan 1, 2024
-32.05 EUR
Jan 1, 2025
-16.82 EUR
The Ascendis Pharma A/S ROA history
YEARROAYoY
-16.82 %-47.52%
-32.05 %-45.03%
-58.32 %+8.97%
-53.52 %+51.37%
-35.36 %-17.32%
-42.76 %+32.73%
-32.22 %-21.01%
-40.79 %-30.55%
-58.72 %+62.94%
-36.04 %+44.26%
-24.98 %+51.77%
-16.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ascendis Pharma A/S Stock analysis

What does Ascendis Pharma A/S do? Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S is one of the most popular companies on Eulerpool.

ROA Details

Understanding Ascendis Pharma A/S's Return on Assets (ROA)

Ascendis Pharma A/S's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Ascendis Pharma A/S's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Ascendis Pharma A/S's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Ascendis Pharma A/S’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Ascendis Pharma A/S stock

Return on Assets (ROA) of Ascendis Pharma A/S is -16.82 % in 2025.

Return on Assets (ROA) of Ascendis Pharma A/S changed from -32.05 % to -16.82 %, representing a -47.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Ascendis Pharma A/S since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Ascendis Pharma A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Ascendis Pharma A/S

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Ascendis Pharma A/S